CPT 81469 Reimbursement & Benchmarks

Headline: Expanded multigene sequencing panel for hereditary breast cancer risk

Lead: CPT 81469 denotes a multigene genomic sequencing panel for hereditary breast cancer-related disorders that includes sequencing of at least 14 genes. The code facilitates testing for inherited risk factors that can influence screening, prevention, and care planning.

What the code represents and national importance: CPT 81469 covers comprehensive genomic sequence analysis focused on hereditary breast cancer-related disorders, capturing key genes such as BRCA1 and BRCA2 among others. Nationally, multigene panels have become central to identifying genetic susceptibility to breast and related cancers, informing risk assessment and specialty care pathways.

Key payers covered: This analysis addresses coverage considerations for major US payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

What readers will learn: The publication provides an overview of the code’s clinical scope and common use cases, compares it to single-gene and smaller-panel testing, summarizes typical sites of service and documentation expectations, notes common billing modifiers, and outlines relevant diagnostic indications. It also highlights related CPT comparators used in hereditary breast and ovarian cancer testing to aid billing and coding decisions.

Data notes: Service line metadata is not provided. Any missing input fields are noted as Data not available in the input.

CPT Code Overview

CPT 81469 is a genomic sequence analysis panel for hereditary breast cancer-related disorders, requiring sequencing of at least 14 genes (for example, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53).

Service Type: Genetic Testing

Typical Site of Service: Laboratory (POS 81)

Clinical Context

A 42-year-old woman with a personal history of early-onset breast cancer and a family history of breast and ovarian cancer is referred for genetic testing to evaluate hereditary breast cancer-related disorders. The clinical workflow: a genetics or oncology provider documents the indication (for example, genetic susceptibility to malignant neoplasm of breast Z15.01 or family history Z80.3), obtains informed consent, and orders a genomic sequencing panel that includes at least 14 genes (e.g., BRCA1, BRCA2, PALB2, TP53). A specimen is collected at the outpatient clinic or sent directly from the office to the laboratory (typical site of service: laboratory POS 81). The laboratory performs the sequencing analysis and reports pathogenic, likely pathogenic, and variants of uncertain significance. Results are returned to the ordering provider for interpretation and management planning; a genetics professional with an appropriate taxonomy may provide counseling.

Coding Specifications

Common modifiers:
26: Professional Component — used when reporting only the professional component of the service (interpretation by a qualified professional).
59: Distinct Procedural Service — used when this test is performed and a separately identifiable service/test is provided on the same day that is not normally reported together.

National commercial mean rates for Blue Cross Blue Shield and BUCA are identical at $80.02 for CPT 81469, while Medicare data is not provided in the input. This places the documented commercial average on par with the BUCA benchmark; no separate Medicare mean is available for direct comparison.

Dispersion across the reported payers is minimal where data exists: the 25th, 50th, and 75th percentiles for both Blue Cross Blue Shield and BUCA are all $80.00, yielding a P75–P25 range of $0.00 and indicating a very tight distribution. Other payers have no data available in the input. The table and chart below present the full breakdown of national mean and percentile values.

Taxonomy Code	Specialty
`207SG0201X`	Medical Genetics, Ph.D. Medical Genetics
`207SC0300X`	Medical Genetics, Clinical Genetics (M.D.)
`207SG0202X`	Medical Genetics, Clinical Biochemical Genetics
`207SG0203X`	Medical Genetics, Clinical Cytogenetics
`207SG0205X`	Medical Genetics, Clinical Molecular Genetics

Related Diagnoses

Z15.01 — Genetic susceptibility to malignant neoplasm of breast

Associated with ordering hereditary breast cancer panels to evaluate inherited risk and identify actionable germline variants.

C50.919 — Malignant neoplasm of unspecified site of unspecified female breast

Relevant when a patient has breast cancer and tumor/clinical history prompts germline testing for hereditary cancer predisposition.

Z80.3 — Family history of malignant neoplasm of breast

Used when family history of breast cancer raises concern for hereditary syndromes and supports panel testing.

Z84.81 — Family history of carrier of genetic disease

Applied when an individual’s family history indicates known carrier status in relatives, prompting consideration of targeted or panel genetic testing.

Z15.02 — Genetic susceptibility to malignant neoplasm of ovary

Relevant because hereditary breast cancer-related panels often include genes (e.g., BRCA1/BRCA2) that confer ovarian cancer risk, supporting combined hereditary risk assessment.

Related CPT Codes

CPT Code	Description	Relation to `81469`
`81211`	BRCA1, BRCA2 gene analysis, full sequence analysis	Alternative single-gene testing for BRCA1/BRCA2 when a focused test is indicated instead of a multi-gene panel; may be ordered if family history points specifically to BRCA genes.
`81213`	BRCA1, BRCA2 gene analysis, known familial variants	Alternative when a known familial pathogenic variant is already identified; used instead of a broad panel when targeted testing suffices.
`81214`	BRCA1, BRCA2 gene analysis, duplication/deletion variants	Complementary or alternative testing to detect large rearrangements in BRCA genes if not covered by the sequencing panel.
`81432`	Hereditary breast cancer-related disorders, genomic sequence analysis panel, 5-50 genes	Overlapping service; `81432` describes panels with 5–50 genes — `81469` requires sequencing of at least 14 genes and may be used when panel size or gene content differs.
`81433`	Hereditary breast cancer-related disorders, duplication/deletion analysis panel, 5-50 genes	Complementary test for copy-number/duplication-deletion analysis across multiple genes; may be used together with sequencing when indicated.

Common use patterns:
Panels such as 81469 are commonly used instead of single-gene tests like 81211 when broader gene coverage is clinically indicated.
81433 may be ordered alongside 81469 when duplication/deletion analysis is required and not fully captured by sequencing alone.
81213 is used as a targeted alternative when a specific familial variant is known and sequencing the full panel is not necessary.

OpenPayer

Summary & Overview

CPT 81469: Hereditary Breast Cancer Multigene Sequencing Panel